Alps Group

Alps Group P/B

The P/B (Price-to-Book Ratio) of Alps Group (ALPS) as of Oct 20, 2026 is -22.52. In the previous year, P/B (Price-to-Book Ratio) was 8.13 — a change of -377.04% (lower).

P/B

-22.52

YoY

-377.04%

Last updated:

P/B (Price-to-Book Ratio) of Alps Group is 2024 -22.52 . P/B (Price-to-Book Ratio) of Alps Group was 2023 8.13 . It decreases by -377.04% lower compared to the previous year.

The Alps Group P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
1.48 USD
Jan 1, 2023
8.13 USD
Jan 1, 2024
-22.52 USD
The Alps Group P/B history
YEARP/BYoY
-22.52-377.04%
8.13+450.48%
1.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc generates revenue through its integrated biotechnology platform Alps Life Sciences Inc., which offers advanced therapies and healthcare solutions. The company provides medical services, wellness solutions, and aesthetic treatments including non-surgical and surgical aesthetic services. Alps Life Sciences Inc. develops and commercializes therapies such as MyImmune (NK cells), CAR-T cells, and diabetes therapeutics, alongside research in mRNA vaccine technology and stem cell advancements like iPSCs. The firm operates molecular and cGMP laboratories for research and cultivation of cell and gene therapies. Alps Group Inc. targets global healthcare providers and patients seeking advanced medical solutions. Its biotechnology pipeline covers diverse areas including cancer therapies, infectious disease treatments, and regenerative medicine. The company's integrated ecosystem combines research, development, medical services, and wellness solutions to improve healthcare outcomes. The firm's aesthetic services cater to individuals seeking cosmetic and wellness procedures, while its medical services address broader healthcare needs. The company's revenue streams include the sale of medical services, wellness solutions, and aesthetic treatments. Alps Life Sciences Inc. focuses on developing therapies for specific health conditions such as diabetes and cancer, with a pipeline that includes mRNA-based vaccines and cell therapies. The molecular and cGMP laboratories support the development and production of these advanced therapies, contributing to the company's product offerings. Alps Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alps Group stock

P/B (Price-to-Book Ratio) of Alps Group is -22.52 in 2024.

P/B (Price-to-Book Ratio) of Alps Group changed from 8.13 to -22.52, representing a -377.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Alps Group since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Alps Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alps Group

All Key Metrics — Alps Group